Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist

…, TB Campbell, G Calandra, G Bridger… - The Journal of …, 2005 - rupress.org
… Thus, we evaluated the mobilizing capability of AMD3100 in comparison with G-CSF, and in
combination with G-CSF, in strains of mice that were reported to differ in responsiveness to G

Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist

…, G Hangoc, GJ Bridger, GW Henson, G Calandra… - Blood, 2003 - ashpublications.org
Stromal cell-derived factor 1 (SDF1/CXCL12) and its cognate receptor, CXCR4, play key
regulatory roles in CD34 + cell trafficking. We investigated whether AMD3100, a selective …

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte …

…, J McCarty, G Bridger, G Calandra - Journal of Clinical …, 2009 - ascopubs.org
Purpose This study evaluates the safety and efficacy of plerixafor (AMD3100), a CXCR4
antagonist, in mobilizing hematopoietic stem cells for autologous stem-cell transplantation in non…

[PDF][PDF] Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence

C Martin, PCE Burdon, G Bridger, JC Gutierrez-Ramos… - Immunity, 2003 - cell.com
In this study we provide evidence that the SDF-1α/CXCR4 chemokine axis is involved in
both the retention of neutrophils within the bone marrow and the homing of senescent …

Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers

…, EJ Fuchs, E Redpath, G Bridger… - Antimicrobial agents …, 2000 - Am Soc Microbiol
AMD-3100, a bicyclam, is a novel agent that uniquely inhibits the entry of human immunodeficiency
virus type 1 (HIV-1) into CD4 + T cells via selective blockade of the chemokine CXCR…

Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer

…, K Scott, G Stamp, GD Wilbanks, S Fricker, G Bridger… - Cancer research, 2002 - AACR
… They are divided into four subfamilies: CC, CXC, C, and CX3C based on the position of
their NH 2 -terminal cysteine residues and bind to seven transmembrane domain G protein-…

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100

…, JL Prior, D Piwnica-Worms, G Bridger… - Blood, The Journal …, 2009 - ashpublications.org
The CXCR4–SDF-1 axis plays a central role in the trafficking and retention of normal and
malignant stem cells in the bone marrow (BM) microenvironment. Here, we used a mouse …

[HTML][HTML] Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4

S Hatse, K Princen, G Bridger, E De Clercq, D Schols - FEBS letters, 2002 - Elsevier
This study was undertaken to demonstrate the unique specificity of the chemokine receptor
CXCR4 antagonist AMD3100. Calcium flux assays with selected chemokine/cell …

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

…, D Cooper, G Bridger, G Calandra… - Blood, The Journal …, 2009 - ashpublications.org
This phase 3, multicenter, randomized (1:1), double-blind, placebo-controlled study evaluated
the safety and efficacy of plerixafor with granulocyte colony-stimulating factor (G-CSF) in …

Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection

…, MJ Glesby, CW Flexner, GJ Bridger… - JAIDS Journal of …, 2004 - journals.lww.com
AMD3100 is a CXCR4 receptor inhibitor with anti–HIV-1 activity in vitro. We tested the safety,
pharmacokinetics, and antiviral effect of AMD3100 administered for 10 days by continuous …